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A B S T R A C T
Purpose
Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML).
Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m2 for remission
induction. Consensus has not been reached on the benefit of higher dosages of cytarabine.
Patients and Methods
The European Organisation for Research and Treatment of Cancer (EORTC) and Gruppo Italiano Malattie
Ematologiche dell’ Adulto (GIMEMA) Leukemia Groups conducted a randomized trial (AML-12; Combina-
tion Chemotherapy, Stem Cell Transplant and Interleukin-2 in Treating Patients With Acute Myeloid
Leukemia) in 1,942 newly diagnosedpatientswithAML, age 15 to 60 years, comparing remission induction
treatment containingdaunorubicin, etoposide, andeither standard-dose (SD) cytarabine (100mg/m2per day
by continuous infusion for 10 days) or high-dose (HD) cytarabine (3,000 mg/m2 every 12 hours by 3-hour
infusion on days 1, 3, 5, and 7). Patients in complete remission (CR) received a single consolidation cycle
containing daunorubicin and intermediate-dose cytarabine (500 mg/m2 every 12 hours for 6 days).
Subsequently, a stem-cell transplantation was planned. The primary end point was survival.
Results
At a median follow-up of 6 years, overall survival was 38.7% for patients randomly assigned to SD
cytarabine and 42.5% for those randomly assigned to HD cytarabine (log-rank test P  .06;
multivariable analysis P  .009). For patients younger than age 46 years, survival was 43.3% and
51.9%, respectively (P .009; multivariable analysis P .003), and for patients age 46 to 60 years,
survival was 33.9% and 32.9%, respectively (P  .91). CR rates were 72.0% and 78.7%,
respectively (P  .001) and were 75.6% and 82.4% for patients younger than age 46 years (P 
.01) and 68.3% and 74.8% for patients age 46 years and older (P  .03). Patients of all ages with
very-bad-risk cytogenetic abnormalities and/or FLT3-ITD (internal tandem duplication) mutation, or
with secondary AML benefitted from HD cytarabine.
Conclusion
HD cytarabine produces higher remission and survival rates than SD cytarabine, especially in
patients younger than age 46 years.
J Clin Oncol 32:219-228. © 2013 by American Society of Clinical Oncology
INTRODUCTION
Cytarabine plays an important role in the treatment
ofpatientswithacutemyeloid leukemia (AML).Ad-
ministration at a daily dose of 100 to 200mg/m2 for
7 to10days incombinationwith3daysof ananthra-
cycline is themost commonlyusedremission induc-
tion regimen. This schedule results in complete
remission (CR) rates of 60% to 80% depending on
age and cytogenetic and molecular features of the
acute leukemia.1,2 Higher doses of cytarabine (2,000
to 6,000mg/m2per day for eight to twelve doses) for
inductionof remissionand/or in consolidationhave
been tested in various AML trials.3-17 Thus far, four
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randomized trialshavebeenreported that evaluated increaseddosages
of cytarabine as part of the induction regimen of previously untreated
patients.14-17 Despite these experiences, definite conclusions on the
value of high-dose (HD) cytarabine remain hard to draw. Possible
reasons are insufficient numbers of patients per trial or more
intensive induction strategies in the control arm.13 On the basis of
the encouraging results of the Australian Leukemia Study Group
reported by Bishop et al,14 the Leukemia Groups of the European
Organisation for Research and Treatment of Cancer (EORTC)
and the Gruppo Italiano Malattie Ematologiche dell’ Adulto
(GIMEMA) conducted a large randomized trial (AML-12; Combi-
nation Chemotherapy, Stem Cell Transplant and Interleukin-2 in
Treating Patients With Acute Myeloid Leukemia) to compare HD
cytarabine versus standard-dose (SD) cytarabine in the induction
regimen. In both arms, patients who achieved CR after one or two
induction courses received a single consolidation course contain-
ing intermediate-dose cytarabine and allogeneic or autologous
stem-cell transplantation (SCT).
PATIENTS AND METHODS
Eligibility
Untreated patients with de novo or secondary AML age 15 to 60 years
were eligible. Main inclusion criteria were morphologically confirmed AML
withbonemarrowcontaining30%ormoreblasts; aWHOperformance status
of 3 or less; no evidence of severe concurrent cardiac, pulmonary, neurologic,
ormetabolicdisordersoruncontrolled infections; andadequate liverandrenal
function tests. Secondary AMLwas defined as AML following hematologic or
Total enrolled
(N = 2,005)
Randomly allocated
(n = 1,942)
Included in efficacy analysis (n = 969)
Included in safety analysis (n = 951)
Included in efficacy analysis (n = 973)
Included in safety analysis (n = 949)
Allocated to SD cytarabine
(n = 969)
Allocated to HD cytarabine
(n = 973)
Induction started (n = 951)
CR achieved (n = 685)
Consolidation received (n = 642)
Postconsolidation received (n = 482)
 Family Unrelated No donor
 donor donor or not
 present found HLA typed
 (n = 244) (n = 44) (n = 397)
 Family Unrelated No donor
 donor donor or not
 present found HLA typed
 (n = 290) (n = 38) (n = 419)
 Allo-SCT Allo-SCT Auto-SCT
performed performed performed
 (n = 172) (n = 19) (n = 261)
 Allo-SCT Allo-SCT Auto-SCT
 performed performed performed
 (n = 190) (n = 19) (n = 283)
Induction started (n = 949)
CR achieved (n = 747)
Consolidation received (n = 695)
Postconsolidation received (n = 523)
Did not receive
allocated therapy
(n = 24)
Did not receive
allocated therapy
(n = 18)
Normal completion (n = 288)
Initial treatment failure (n = 172)
)071 = n( RC retfa espaleR
)161 = n( yticixoT
Further treatment refusal (n = 57)
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)86 = n( nosaer rehtO
Ineligible for the study (n = 6)
)0 = n( nwonknU
Normal completion (n = 309)
Initial treatment failure (n = 126)
)151 = n( RC retfa espaleR
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Further treatment refusal (n = 83)
Treatment protocol violation (n = 25)
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Ineligible for the study (n = 1)
)1 = n( nwonknU
All patients from 3 centers were excluded 
due to poor data in majority of them
(n = 63)
Fig 1. Disposition of patients in each
arm. Allo-SCT; allogeneic stem-cell trans-
plantation; auto-SCT, autologous SCT; CR,
complete remission; HD, high dose; SD,
standard dose.
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nonhematologicmalignanciesorafter exposure tochemotherapyor radiation.
Patients with promyelocytic leukemia, AML after myelodysplastic syndrome
ofmore than 6months duration, or AML/blast crisis after chronicmyelopro-
liferative disease or during concomitant other progressive malignant disease
were excluded (Fig 1).
The study was approved by the internal review boards of EORTC and
GIMEMAand the ethical committee of each participating institution andwas
conducted in accordance with the Declaration of Helsinki. All patients signed
the informed consent form.
Study Design
The study aimed to compare efficacy and toxicity of an induction regi-
men that contained HD cytarabine versus SD cytarabine. Primary end point
was overall survival (OS). Secondary end points were CR rate, disease-free
survival (DFS), toxicity, and rate of autologous or allogeneic SCT in each arm.
Patients who fulfilled the eligibility criteria were randomly assigned to the
standard or experimental arm at the EORTC Headquarters in Brussels, Bel-
gium. At random assignment, patients were stratified according to center, age
(15 to45years v46 to60years),WHOperformance status (grade0 to1 vgrade
2 v grade 3), and total leukocyte count ( 25 v 25 to 99.9 v 100 109/L) by
using a minimization technique (Fig 2).
Thebasis forour standardremission inductionregimenwas the standard
arm of the EORTC-GIMEMA Study AML-10 (Daunorubicin Versus Mitox-
antrone Versus Idarubicin As Induction and Consolidation Chemotherapy
forAdultsWithAcuteMyeloidLeukemia:TheEORTCandGIMEMAGroups
Study AML-10),2 which included daunorubicin, etoposide, and 10 days of
cytarabine. At that time, the standard arm in the AML-10 trial showed the
lowest toxicity with equal efficacy compared with the experimental arms.
Furthermore, this schedule had important similarities with the standard arm
of the Australian trial.14 In the experimental arm, 4 days of HD cytarabine
replaced the 10 days of SD cytarabine similar to the experimental arm of the
Australian trial. Thus, remission induction consisted of daunorubicin (50
mg/m2 per day as a 5-minute intravenous [IV] infusion on days 1, 3, and 5)
and etoposide (50mg/m2 per day by 1-hour IV infusion on days 1 through 5)
inbotharms, in combinationwitheither10daysof cytarabine (100mg/m2per
day as continuous IV infusion) in the standard arm (SD cytarabine) or cytar-
abine (3,000mg/m2 every 12 hours as a 3-hour IV infusion ondays 1, 3, 5, and
7) in the experimental arm (HD cytarabine). Assessment of response was
planned by day 31 of induction. Criteria for response and relapse followed the
Report of the National Cancer Institute-Sponsored Workshop.18 In case of
partial remission, a second identical inductioncoursewasgiven.OnceCRwith
or without full hematologic recovery was achieved, a single consolidation
course identical with the consolidation course of EORTC-GIMEMA AML-
10,2 consisting of intermediate-dose cytarabine (500mg/m2 every 12 hours as
a 2-hour IV infusion on days 1 through 6) plus daunorubicin (50 mg/m2 per
day as a 5-minute infusion on days 4 through 6) was administered. In some
centers, allogeneic SCT (allo-SCT) was strongly recommended after consoli-
dation for patients younger than age 50 years or up to age 60 years with an
HLA-compatible family donor, or for patients without a family donor who
hadAMLwithchromosomeabnormalities involving3q, 5, t(6;9), t(9;22), 7, or
11q23 complex abnormalities, or for those with a matched unrelated donor
who needed a second remission induction course. All patients not eligible for
allo-SCT were planned for autologous SCT. Mobilization and collection of
autologous stem cells of those patients was scheduled during the recovery
phase of consolidation. Lenograstim (150 g/m2 per day) was given by daily
subcutaneous injections from day 20 of consolidation until completion of the
blood stem-cell harvest. All CR patients without a suitable stem-cell donor
were eligible for a second random assignment involving 5 days of low-dose
subcutaneous interleukin-2 as monthly courses for a year or until relapse.
Results of the second random assignment are not within the scope of
this report.
End Points
OSwasdefinedas the time interval fromrandomassignmentuntil death,
whatever the cause. Follow-up of patients still alive was censored at the mo-
mentof last visit or contact.DFSwasdefinedas the time fromCRuntil thefirst
relapse or death as a result of any cause. For patients still alive in first CR, DFS
was censored on the date of last visit or contact. Because allo-SCT was inte-
grated into the treatment scheme, follow-upofpatientswasnotcensoredat the
date of allo-SCT. Event-free survival (EFS) for patients in CR was defined as
DFS,whereas for patientswhodid not reachCR, EFSwas set as being an event
at time zero. The duration of hematologic recovery was defined as the time
from the first day of the chemotherapy course until neutrophil level wasmore
than 0.5  109/L or platelet level was more than 10  109/L or more than
100 109/L; patients without recovery were censored at day 99. Toxicity was
evaluated according to Common Toxicity Criteria version 2.0.
Statistical Analysis
The studywas powered to detect an 8% treatment difference (from35%
to 43%) in the 5-year OS rate, corresponding to a hazard ratio (HR) of 0.80
(two-sided, 5%; power, 95%) and a treatment-age (15 to 45 v 46 to 60 years)
interaction with an 80% power. A total of 2,000 randomly assigned patients
was required to follow 1,100 of them until death.
Time-to-event outcomes were computed by using the Kaplan-Meier
technique andwere compared by using the two-tailed log-rank test.19 Cumu-
lative incidence of relapse and of the incidence of death in CRwere estimated
by using competing risk methods.19 Forest plot technique was used to obtain
treatment HR estimate, along with its 95% or 99% CI, and to perform sub-
group analyses. The Cox proportional hazards model stratified by cytogenet-
ic-molecular features was used to adjust the treatment comparison by initial
patient-disease features. Fisher’s exact test and linear logistic regressionmodel
were used to compare the CR rates after induction.
All efficacy analyses were performed according to the intention-to-treat
principle (all patients randomly assignedwere included, except for all patients
[n  63] from three centers with extremely poor data reporting). To avoid
selection bias, analysis of the impact of allo-SCT on the outcome was per-
formed according to the availability of a donor, and treatment comparison
regardingDFSwasperformed separately inpatientswith andwithout adonor.
Data for patients who started the protocol treatment were used for response
rate, EFS, and adverse event comparison, and data for patients who reached
CR were used for DFS and time-to-recovery comparisons. SAS 9.3 software
(SAS Institute, Cary, NC) was used for the statistical analyses.
RESULTS
Patients
Between September 1999 and January 2008, 1,942 patients were
randomlyassigned:872 from22EORTCand1,070 from42GIMEMA
Allo-SCT
Auto-PBSCT
+ IL2
Auto-PBSCT
YES
NO
†R2
*R1
SD cytarabine
HD cytarabine
ID
cytarabine
ID
cytarabine
Stem cell
harvest
Donor available
and age < 50 yrs
Fig 2. Trial design of the European Organisation for Research and Treatment of
Cancer/Gruppo Italiano Malattie Ematologiche dell’ Adulto (EORTC-GIMEMA)
AML-12 trial. Treatment schedules are as follows: standard-dose (SD) cytarabine
induction: daunorubicin (50 mg/m2 per day as a 5-minute intravenous [IV] infusion on
days 1, 3, and 5) plus etoposide (50 mg/m2 per day by 1-hour IV infusion on days 1
through 5) plus10 days of cytarabine (100 mg/m2 per day as continuous IV infusion);
high-dose (HD) cytarabine induction: daunorubicin (50 mg/m2 per day as a 5-minute
IV infusion on days 1, 3, and 5) plus etoposide (50 mg/m2 per day by 1-hour IV
infusion on days 1 through 5) plus cytarabine (3,000 mg/m2 every 12 hours as a
3-hour IV infusion on days 1, 3, 5, and 7); intermediate-dose (ID) cytarabine
consolidation: cytarabine (500 mg/m2 every 12 hours as a 2-hour IV infusion on days
1 through 6) plus daunorubicin (50 mg/m2 per day as a 5-minute infusion on days 4
through 6). Allo-SCT, allogeneic stem-cell transplantation; auto-PBSCT, autologous
peripheral blood SCT; IL-2, interleukin-2 (4  106 IU/m2 subcutaneous injection on
day 1 8 106 IU/m2 subcutaneous injections on days 2 through 5, every 4 weeks,
for 1 year). (*) R1, first randomization; (†) R2, second randomization.
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centers. Their median age was 45 years (range, 15 to 60 years). As
induction, 969 patients were randomly assigned to receive the SD
cytarabine and 973 to receive the HD cytarabine regimen. The two
treatment arms were matched with respect to baseline characteristics
(Table 1). Fifty-three randomly assigned patients were ineligible—25
(2.6%) in the SD cytarabine and 28 (2.9%) in the HD cytarabine
arm—but they were included in themain intention-to-treat analysis.
Reasons for ineligibility were wrong diagnosis (acute lymphoblastic
leukemia, chronicmyeloblastic leukemia, acute promyelocytic leuke-
mia, ormyelodysplastic syndrome in 40 patients and other reasons in
13 patients.
Treatment Phases and Outcomes
A total of 1,900 patients started induction treatment: 951 in the
SD cytarabine and 949 in the HD cytarabine arm (Fig 1). Reasons for
not starting induction were refusal (n  4), death before treatment
(n 10), ineligibility (n 21), and other (n 7). Details regarding
treatment phases and outcomes in both randomly assigned arms are
shown in Table 2. A significantly higher percentage of patients receiv-
ingHDcytarabine achievedCR(P .009).Thedeath rate after oneor
two inductioncourseswas similar inbotharms.Among1,432patients
who achieved CR, consolidation course was administered to 1,337
patients: 93.7% in the SD cytarabine arm and 93.0% in the HD
cytarabine arm. Reasons for not receiving consolidation were death
before treatment (n  7), no longer in CR (n  14), persisting
infection(n34),persistingorgan failure (n7),neurologic toxicity
(n 7), and other (n 26).
At a median follow-up of 6 years, 1,091 patients had died: 568
(59.7%) in the SD cytarabine arm and 523 (55.2%) in theHD cytara-
bine arm. The OS rate at 6 years was 40.6% for all patients: 38.7% in
theSDcytarabinearmand42.5%in theHDcytarabinearm(HR,0.89;
P .06). Comparison of treatment outcome stratified for cytogenetic
features and adjusted for several other risk factors was significant in
favor of HD cytarabine (HR, 0.86; P .009; Fig 3A).
Subgroup Analysis
Planned subgroup analyses according to age group were per-
formed fordifferent endpoints (Tables2and3,Fig3BandFig4).Both
Table 1. Baseline Characteristics of all Patients, Patients Age 15-45 Years, and Patients Age 46-60 Years, by Randomized Treatment Arm
Characteristic
All Patients Patients Age 15-45 Years Patients Age 46-60 Years
SD Cytarabine
(n  969)
HD
Cytarabine
(n  973)
SD Cytarabine
(n  490)
HD
Cytarabine
(n  490)
SD Cytarabine
(n  479)
HD
Cytarabine
(n  483)
No. % No. % No. % No. % No. % No. %
Male sex 504 52 508 52.2 244 49.8 252 51.4 260 54.3 256 53.6
Age, years
Median 45 45 36 34 54 53
Range 15-60 15-60 15-45 15-45 46-60 46-60
WHO performance status 0-1 871 89.9 872 89.6 438 89.4 454 92.7 433 90.4 418 86.5
Type of leukemia
De novo AML 906 93.5 919 94.5 466 95.1 470 95.9 440 91.9 449 93
Secondary AML 58 6 47 4.8 22 4.5 17 3.5 36 7.5 30 6.2
WBCs at diagnosis  109/L
 25 566 58.4 574 59 270 55.1 282 57.6 296 61.8 292 60.5
25-99.9 287 29.6 283 29.1 147 30 149 30.4 140 29.2 134 28.5
 100 116 12 116 11.9 73 14.9 59 12 43 9 57 11.8
Median 16.3 14.8 18.6 17.1 14 13.8
Range 0.3-393 0.3-358 0.5-393 0.3-358 0.3-269 0.3-351
FLT3-ITD mutation
Negative 487 50.3 469 48.2 252 51.4 244 49.8 235 49.1 225 46.6
Positive 126 13.0 137 14.1 68 13.9 68 13.9 58 12.1 69 14.3
Not done 356 36.7 367 37.7 170 34.7 178 36.3 186 38.8 189 39.1
Cytogenetics/FLT3-ITD
Good risk 97 10 93 9.6 70 14.3 65 13.3 27 5.6 28 5.8
Intermediate risk 287 29.6 260 26.7 140 28.6 119 24.3 147 30.7 141 29.2
Bad risk 107 11 94 9.7 61 12.4 61 12.4 64 13.4 74 15.3
Very bad risk/FLT3-ITD 223 23 256 26.3 106 21.6 101 20.6 95 19.8 114 23.6
Unknown risk 255 26.3 270 27.7 109 22.2 144 29.4 146 30.5 126 26.1
Donor availability in CR patients only 685 747 366 399 319 348
No donor present 330 338 182 187 148 151
Family donor present 244 290 137 157 107 133
Unrelated donor present 44 38 31 29 13 9
No HLA typing 67 81 16 26 51 55
Abbreviations: AML, acute myeloid leukemia; CR, complete remission; HD, high dose; ITD, internal tandem duplication; SD, standard dose.
Good risk includes the abnormalities inv(16) and t(8;21). Intermediate risk includes normal karyotypes and those with Y only, without FLT3-ITD mutation. Very
bad risk/FLT3-ITD includes presence of5/5q and7/7q, complex abnormalities, 3q, t(6;9), t(9;22), and 11q23, and all patients with an FLT3-ITD mutation. Other
abnormalities were pooled into a separate “bad risk” cytogenetic risk group. Patients with unknown, not done, or unsuccessful cytogenetic tests were grouped
together as “unknown risk.”
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age (P .06) anddisease type (denovo v secondaryAMLP .05)had
an impact on treatment comparison regarding survival (Fig 4). For
patients age 15 to 45 years, HD cytarabine significantly improved the
CRrate (82.4% v75.6%;P .01), the 6-yearEFS rate (43.6% v35.1%;
P .003), and the 6-year OS rate (51.9% v 43.3%; P .009); in older
patients, only theCR ratewas higher in theHDcytarabine arm. In the
younger age group, HD cytarabine increased the 6-year DFS rate
comparedwith SDcytarabine (52.8% v 46.4%;P .07) by decreasing
the relapse incidence by 5% (40.3% v 45.3%) and without increasing
the incidence of death in CR (Table 2). In contrast, in the older age
group, the decrease of 5.1% (46.0% v 51.1%) in relapse incidence was
counterbalanced by an increase of 4.6% (18.5% v 13.1%) in the inci-
dence of death in CR (Table 2). Furthermore, in the younger age
group, HD cytarabine improved OSmore in patients with secondary
AML (HR, 0.23; P .005) than in patients with de novo AML (HR,
0.83; P .04).
Interestingly, improvement of the CR rate in patients with sec-
ondary AML was detected both in younger (odds ratio, 5.99) and in
older patients (odds ratio, 3.75), as was the OS in patients with
very-bad-risk cytogenetic abnormalities and/or FLT3-ITD (internal
tandem duplication) mutation both in younger (HR, 0.70; P .02)
and older patients (HR, 0.80, P  .14). These findings were con-
firmed by multivariable analyses (Table 3), and also when eligible
patients who started the allocated treatment were considered (data
not shown).
DFS According to Donor Availability and Age Group
In the younger age group, availability of a family donor did
improve the outcome in both randomly assigned arms. In the SD
cytarabine arm, the 6-year DFS rate was 57.4% for patients with a
donor and 39.5% for patients without a donor; in the HD cytarabine
arm, the 6-year DFS rates were 62.6% and 46.4%, respectively. The
estimated treatmentHRwas 0.84 in patients with a donor and 0.83 in
patients without a donor.
For the older age group, the 6-year DFS was approximately 35%
in patients with or without a family donor, whether they receivedHD
or SD cytarabine. The estimated treatment HR was close to 1 in each
group.Addingpatientswithunrelateddonors to the groupof patients
with related donors did not significantly alter the treatment compari-
sons (data not shown).
Adverse Events
Grade3and4nonhematologic toxicitiesof the inductioncourses
were not different in the two randomly assigned arms except for
conjunctivitis grade 2 to 3 toxicity,whichoccurredmore frequently in
theHDcytarabine armthan in theSDcytarabine arm(12.4% v0.5%).
Grade 3 and 4 infectious complications were reported in 67.6% of
patients receiving SD cytarabine and in 66.2% of those receiving HD
cytarabine. In the twoage groups (15 to45 and46 to60 years), adverse
event profiles in the two randomly assigned arms were remarkably
similar.Median time to neutrophil recovery ( 0.5 109/L) after the
Table 2. Phases of Treatment and Outcomes, Overall and by Age Group, by Randomized Treatment Arm
Induction Treatment
All Patients Patients Age 15-45 Years Patients Age 46-60 Years
SD Cytarabine HD Cytarabine SD Cytarabine HD Cytarabine SD Cytarabine HD Cytarabine
No. % No. % No. % No. % No. % No. %
Patients who started induction 951 100 949 100 484 100 484 100 467 100 465 100
CR after one course 649 68.2 715 75.3 351 72.5 380 78.5 298 63.8 335 72
CR after one or two courses 685 72 747 78.7 366 75.6 399 82.4 319 68.3 348 74.8
Resistant disease 180 18.9 126 13.3 78 16.1 50 10.3 96 20.6 70 15.1
Death during induction phase 86 9 74 7.8 34 7.0 27 5.5 52 11.1 47 10.1
Consolidation treatment (eligible) 685 100 747 100 366 100 399 100 319 100 348 100
Patients who started consolidation 642 93.7 695 93 346 94.5 372 93.2 296 92.8 323 92.8
Postconsolidation treatment 482 75.1 523 75.5 268 77.5 288 77.4 214 72.3 235 72.7
Autologous SCT 261 283 135 149 126 134
Intensive chemotherapy 30 31 13 18 17 13
Allogeneic SCT (related donor) 172 190 108 104 64 86
Allogeneic SCT (unrelated donor) 19 19 12 17 7 2
Outcome from first CR
Still alive in first CR 292 42.6 339 45.4 172 47.0 214 53.6 120 37.6 125 35.9
Relapse 321 46.9 315 42.2 164 44.8 157 39.3 157 49.2 158 45.4
Death in first CR 72 10.5 93 12.4 30 8.2 28 7.0 42 13.2 65 18.7
DFS rate at 6 years 41.6 44.7 46.4 52.8 35.8 35.5
HR 0.93 95% CI,
0.81 to 1.06
0.83 99% CI,
0.64 to 1.08
1.03 99% CI,
0.80 to 1.33
Log rank P 0.27 0.07 0.73
HR 0.88 95% CI,
0.77 to 1.01
0.79 99% CI,
0.60 to 1.03
0.99 99% CI,
0.77 to 1.27
Wald P 0.08 0.02 0.89
Relapse incidence at 6 years 47.9 43.0 45.3 40.3 51.1 46.0
Death in CR incidence at 6 years 10.5 12.4 8.3 7.0 13.1 18.5
Abbreviations: CR, complete remission; DFS, disease-free survival; HD, high dose; HR, hazard ratio; ITD, internal tandem duplication; SCT, stem-cell transplantation;
SD, standard dose.
Cox model stratified by cytogenetics/FLT3-ITD, and adjusted by age (when all patients were analyzed).
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startoffirst inductioncoursewas27days in theSDcytarabinearmv25
days in the HD cytarabine arm. Median times to platelet recovery
( 100 109/L)were 29days in the SDcytarabine armand27days in
the HD cytarabine arm.
After the consolidation course, grade 3 to 4 nonhematologic
toxicities were similar in both arms. Median time to neutrophil
recovery ( 0.5 109/L) was 22 days in both arms.Median time to
platelet recovery in the SD v HD cytarabine arms was 20 v 22 days
to reach 10  109/L platelets and 31 v 38 days to reach 100 
109/L platelets.
DISCUSSION
This study demonstrates that at a median follow-up of 6 years in
patients age 15 to 60 years with untreated AML, induction of remis-
sion using HD cytarabine in combination with daunorubicin and
etoposide is associated with higher CR rate and survival chance than
using the same regimen with SD cytarabine and without significant
increase in toxicity. Survival advantage is significant for patients
younger than age 46 years and for patients with secondary AML or
with AML associated with very-bad-risk cytogenetic abnormalities or
FLT3-ITDmutation.
Our results differ from previously published randomized trials
onHD cytarabine in the induction regimen.14-17Main differences are
the number of induction cycles and the total doses of cytarabine
administered before establishing treatment response and the number
of patients per randomized arm (for details, see Appendix Table A1,
online only). We were impressed by the results of the Australian
Leukemia Study Group,14 which randomized remission induction
with SD cytarabine and HD cytarabine, both combined with dauno-
rubicin and etoposide, followed (in the case of CR) by two mild
consolidation courses and 2 years of maintenance therapy. CR rates
were 74% in the SD cytarabine arm and 71% in the HD cytarabine
arm.Toxicitywas significantlyhigher afterHDcytarabine, and18%of
patients in the HD cytarabine arm died during induction compared
with 11% in the SD cytarabine arm (P .09). For patients receiving
HD cytarabine, significantly longer duration of remission, DFS, and
survival forCRpatientswas reported.OSwasnot statistically different
between the two arms. The relatively lownumber of patients included
in the trial prevented further long-term analysis. We hypothesized
that improvement in supportive care during induction together
with availability of more intensive postremission strategies might
decrease induction death and relapse rates. Furthermore, the in-
clusion of a larger number of patients would allow proper evalua-
tion of a potential therapeutic advantage of HD cytarabine in
induction therapy. On the basis of these arguments, we designed a
large phase III study using both arms of the Australian protocol as
well as the control arm of our most recent EORTC-GIMEMA
AML-10 study.
In this study, stratification for age (15 to 45 and 46 to 60 years) at
registrationallowedprofoundstatistical analysis in the twosubgroups.
In patients younger than age 46, the beneficial effect ofHD cytarabine
induction was consistently and significantly observed in terms of CR
rate, EFS, and OS; in patients age 46 to 60 years, the positive effect of
the increase inCR ratewas counterbalanced by an increase in death in
CR, translating into a small improvement in OS. Younger patients
were expected to fare better with intensive chemotherapy and trans-
plantation than older patients.1,2 However, more intensive treatment
and higher remission rates are usually not translated into longer sur-
vival. An age effect on survival was not reported by the Australian
Leukemia Study Group.15 Only the HOVON-SAKK (Cytarabine
Dose forAcuteMyeloid Leukemia) study17 showed a trend in survival
improvement in favor of HD cytarabine in patients younger than 36
years: 52% 5-year OS in the HD cytarabine arm and 42% in the
intermediate-dose cytarabine arm (HR, 0.73, P .14). Although the
HOVON-SAKK study did not show major differences between the
intermediate-dose and HD cytarabine arms, it remains an unan-
swered question whether a comparison between SD cytarabine and
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intermediate-dose cytarabine in inductionwouldhave led to the same
results as shown with HD cytarabine in our study.
In contrast to the significantly increased toxicity observed in
earlier trials,14,15,17 except for significant conjunctivitis, we report that
HD cytarabine, in the way it was administered as it was in our study,
was not associated with higher toxicity including death during induc-
tion.Asmentioned, this could reflect the inclusionof strict supportive
guidelines in the treatment protocol. Longer duration of platelet
recovery was documented only after the consolidation course. This
finding has also been reported in the Australian Study,14 the
EORTC-GIMEMA AML-10 trial2 and the HOVON-SAKK trial,17
and may be as a result of increased stem-cell toxicity.
In the younger age group, donor versus no-donor analysis
showed that availability of a donor improved the chances to remain
alive in first CR equally in both randomized arms. In the older age
group, a better antileukemic effect by allo-SCTmay have been coun-
terbalanced by a higher death rate as a result of transplantation com-
plications. The number of transplantations using unrelated donor
stem cells was too small to affect the results.
The planned subgroup analysis also showed clinically important
superiority of HD cytarabine induction in patients with AML with
very-bad-risk cytogenetic abnormalities, with FLT3-ITD mutation,
and in patients with secondary AML. This is a particularly important
finding since, thus far, only allo-SCT has been proven to favorably
affect the dismal prognosis of these patients with bad-risk AML.20
In conclusion, HD cytarabine in the induction treatment of pa-
tients age15 to45yearswithAMLsignificantly increased response rate
and survival without significant increase in grade 3 to 4 toxicities.
Treatment effect: P = .06
HD-cytarabine better  SD-cytarabine better
0.25 0.5 1.0 2.0 4.0
*IC & RH scitsitatS stneitaP/stnevE 
 HD-Cytarabine SD-Cytarabine (O-E) Var. (HD-Cytarabine : SD-Cytarabine) HR (99% CI)
Age, years
)00.1 ot 36.0( 97.0 5.321 9.82- 094/962 094/622 54-51  
)22.1 ot 08.0( 99.0 5.451 5.1- 974/803 384/113 06-64  
                      Heterogeneity test (df = 1) : P = .06
Type of leukemia
)80.1 ot 87.0( 29.0 1.162 8.12- 609/535 919/115 LMA ovon ed  
)70.1 ot 92.0( 65.0 7.51 2.9- 85/04 74/32 LMAs  
                      Heterogeneity test (df = 1) : P = .05
WBC, × 109/L
)41.1 ot 67.0( 39.0 9.951 2 .21- 665/323 475/813 52 <  
)01.1 ot 26.0( 28.0 3.08 5.51- 782/471 382/841 99-52  
  ≥ )93.1 ot 06.0( 29.0 6.73 3.3- 611/08 611/17 001 
                      Heterogeneity test (df = 2) : P > .1
Cytogenetics
)86.1 ot 24.0( 48.0 41 4.2- 79/13 39/52 dooG  
)90.1 ot 36.0( 38.0 8.98 6.61- 153/891 023/261 etaidemretnI  
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                      Heterogeneity test (df = 4) : P > .1
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Fig 4. Subgroup analyses of overall survival
for high-dose (HD) cytarabine versus standard-
dose (SD) cytarabine in the intention-to-treat
population. (*) 95%CI for totals and subtotals;
99% CI elsewhere. AML, acute myeloid leu-
kemia; HR, hazard ratio; ITD, internal tandem
duplication; O-E, observed-expected; sAML,
secondary acute myeloid leukemia; Var.,
variance.
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